Peter K. Wung

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

François-Xavier Lescure, Hitoshi Honda, Robert Fowler et al. · The Lancet Respiratory Medicine · 2021 · 248 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

A randomised, double-blind, placebo-controlled, 24-week, phase II, proof-of-concept study of romilkimab (SAR156597) in early diffuse cutaneous systemic sclerosis

Yannick Allanore, Peter K. Wung, Christina Soubrane et al. · Annals of the Rheumatic Diseases · 2020 · 108 citations · Full text

Life Sciences, Clinical Sciences, Immunology +16

Herpes zoster in immunocompromised patients: Incidence, timing, and risk factors

Peter K. Wung, Janet T. Holbrook, Gary S. Hoffman et al. · The American Journal of Medicine · 2005 · 99 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +13

SAR156597 in idiopathic pulmonary fibrosis: a phase 2 placebo-controlled study (DRI11772)

Ganesh Raghu, Luca Richeldi, Bruno Crestani et al. · European Respiratory Journal · 2018 · 99 citations · Full text

Veterinary Medicine, Immunology, Pharmacotherapy +13

A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis

Daniël Blockmans, Arathi R. Setty, Wolfgang Schmidt et al. · New England Journal of Medicine · 2025 · 80 citations · Full text

Medicine, Pharmacotherapy, Immunopathology +12